Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation

Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation

Wang Chun Kwok,1 Terence Chi Chun Tam,1 James Chung Man Ho,1 David Chi Leung Lam,1 Mary Sau-Man Ip,1 Pak Leung Ho2 1Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People’s Republic of China; 2Department of Microbiology and...

Full description

Bibliographic Details
Main Authors:	Kwok WC, Tam TCC, Ho JCM, Lam DCL, Ip MSM, Ho PL
Format:	Article
Language:	English
Published:	Dove Medical Press 2024-01-01
Series:	International Journal of COPD
Subjects:	asthma copd bronchiectasis interstitial lung disease molnupiravir nirmatrelvir-ritonavir covid-19
Online Access:	https://www.dovepress.com/real-world-effectiveness-study-of-nirmatrelvir-ritonavir-or-molnupirav-peer-reviewed-fulltext-article-COPD

Similar Items

Real-World Study on Effectiveness of Molnupiravir and Nirmatrelvir–Ritonavir in Unvaccinated Patients with Chronic Respiratory Diseases with Confirmed SARS-CoV-2 Infection Managed in Out-Patient Setting
by: Wang Chun Kwok, et al.
Published: (2023-02-01)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022-12-01)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
by: Maria Mazzitelli, et al.
Published: (2023-01-01)

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study
by: Mei-Ping Chen, et al.
Published: (2024-02-01)

Effectiveness of molnupiravir vs nirmatrelvir-ritonavir in non-hospitalised and hospitalised patients with COVID-19: a target trial emulation studyResearch in context
by: Eric Yuk Fai Wan, et al.
Published: (2023-10-01)

Real-World Experience of the Comparative Effectiveness and Safety of Molnupiravir and Nirmatrelvir/Ritonavir in High-Risk Patients with COVID-19 in a Community Setting
by: Yoshikazu Mutoh, et al.
Published: (2023-03-01)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
by: Ivan Gentile, et al.
Published: (2022-10-01)

Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
by: Vassiliki Spiliopoulou, et al.
Published: (2023-03-01)

MOLNUPIRAVIR (MOL) COMPARADO A NIRMATRELVIR/RITONAVIR (NIRI) PARA COVID-19 EM PACIENTES DE ALTO RISCO COM MALIGNIDADE HEMATOLÓGICA NA EUROPA: UMA ANÁLISE PAREADA DO REGISTRO EPICOVIDEHA
by: Jon Salmanton-García, et al.
Published: (2023-10-01)

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
by: Sydney Paltra, et al.
Published: (2024-01-01)

Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
by: Karolina Akinosoglou, et al.
Published: (2022-11-01)

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023-05-01)

Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases
by: Kwok WC, et al.
Published: (2023-01-01)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
by: Éva Bakos, et al.
Published: (2023-07-01)

Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients
by: José Luis Piñana, et al.
Published: (2023-10-01)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024-01-01)

Post nirmatrelvir/ritonavir erythema multiforme in a patient with coronavirus disease infection
by: José Wagner Leonel Tavares-Júnior, et al.
Published: (2023-06-01)

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
by: Yue Yat Harrison Cheung, et al.
Published: (2024-01-01)

Managing nirmatrelvir/ritonavir (Paxlovid) interactions in general practice
by: Dagmara Mirowska-Guzel, et al.
Published: (2023-09-01)

The Efficacy and Safety of Nirmatrelvir/Ritonavir Against COVID-19 in Elderly Patients
by: Xiang Z, et al.
Published: (2024-01-01)

Nirmatrelvir–Ritonavir Reduced Mortality in Hospitalized Patients with COVID-19 During the Omicron Outbreak: Real-World Evidence from Beijing
by: Zhang Y, et al.
Published: (2024-04-01)

The Clinical Efficacy and Safety of Anti-Viral Agents for Non-Hospitalized Patients with COVID-19: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
by: Chih-Cheng Lai, et al.
Published: (2022-08-01)

Comparison of Azvudine and Nirmatrelvir/Ritonavir and Combined Use in Patients with COVID-19
by: Hu CY, et al.
Published: (2023-12-01)

Efficacy and safety of Nirmatrelvir/Ritonavir for treating the Omicron variant of COVID-19
by: Chaochao Qiu, et al.
Published: (2023-07-01)

Joint analysis of vaccination effectiveness and antiviral drug effectiveness for COVID-19: a causal inference approach
by: Yue Yat Harrison Cheung, et al.
Published: (2024-06-01)

Antiviral effectiveness and survival correlation of azvudine and nirmatrelvir/ritonavir in elderly severe patients with COVID-19: a retrospective real-world studyResearch in context
by: Shuxia Wang, et al.
Published: (2024-03-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2
by: Hui Li, et al.
Published: (2023-10-01)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022-12-01)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022-02-01)

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
by: Zhao X, et al.
Published: (2023-09-01)

Update on COVID-19 Therapy in Pediatric Age
by: Susanna Esposito, et al.
Published: (2022-12-01)

Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
by: Carsten Schade Larsen
Published: (2022-09-01)

Effectiveness, Tolerability and Prescribing Choice of Antiviral Molecules Molnupiravir, Remdesivir and Nirmatrelvir/r: A Real-World Comparison in the First Ten Months of Use
by: Cosmo Del Borgo, et al.
Published: (2023-04-01)

Evaluation of nirmatrelvir + ritonavir therapy in patients with mild to moderate COVID-19
by: T.M. Levina, et al.
Published: (2024-03-01)

Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System
by: Haley J. Appaneal, et al.
Published: (2024-01-01)

The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
by: Anna Gidari, et al.
Published: (2022-07-01)

Is Azvudine Comparable to Nirmatrelvir-Ritonavir in Real-World Efficacy and Safety for Hospitalized Patients with COVID-19? A Retrospective Cohort Study
by: Qinqin Zhao, et al.
Published: (2023-07-01)

Safety, efficacy, and pharmacokinetics of nirmatrelvir and ritonavir in patients with severe COVID-19 and renal impairment: A case report
by: Ren Zheng, et al.
Published: (2024-03-01)

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
by: Chih-Wei Lin, et al.
Published: (2023-12-01)